Preclinical: NXP800 for advanced PCa

[Maxone73]

NXP800, a novel drug developed by the Institute of Cancer Research, shows promise in treating hormone-resistant prostate cancer. By targeting heat shock proteins (HSPs), which help cancer cells survive under stress, NXP800 disrupts tumor growth and allows therapies to regain effectiveness. In preclinical studies, the drug reduced tumor growth by up to 70% and delayed progression, offering hope for patients with aggressive disease. Already in clinical trials for other cancers, NXP800’s repurposing for prostate cancer could accelerate its availability, potentially extending lives and improving quality of life for advanced-stage patients.prostatewarriors.com/2025/0...

[Broccoli24]

yet more exciting developments… this one is looks very promising for giving us many more years. Thanks for posting, Max

[Ian99]

Hi Max. I saw this today in Uk press and as usual you’re on it already! This drug reminds me of parp inhibitors (Lynparza) which also disrupt the cancer cell repair process. But this nxp800 may be more targeted if HSPs are associated only with cancer cells and not ordinary cells.

[Maxone73 in reply to Ian99]

It's just a matter of when bro!! Hopefully soon!